Hyderabad Telangana, India

Amit Antarkar

This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignees: Mylan Laboratories Limited, Viatris Inc.. Active years: 2026.

USPTO Granted Patents = 3 

% Patents Active = 66.7

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Inventor Amit Antarkar

Introduction

Amit Antarkar is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pain management through his innovative inventions. With a total of 3 patents, his work focuses on improving the treatment and management of pain.

Latest Patents

Amit's latest patents include methods for using meloxicam for pain treatment and management. This invention relates to a method for managing various types of pain, such as acute pain, post-operative pain, or post-procedure pain, by administering meloxicam. Another significant patent is a pharmaceutical composition comprising meloxicam, which is designed for the treatment of acute pain. This composition includes at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.

Career Highlights

Throughout his career, Amit has worked with prominent companies in the pharmaceutical industry, including Mylan Laboratories Limited and Viatris Inc. His experience in these organizations has contributed to his expertise in developing effective pain management solutions.

Collaborations

Amit has collaborated with several professionals in his field, including Abhijit Deshmukh and Jeffrey P. Smith. These collaborations have further enhanced his innovative capabilities and broadened his impact on pain management.

Conclusion

Amit Antarkar's contributions to pain management through his patents demonstrate his commitment to improving healthcare solutions. His work continues to influence the pharmaceutical industry and offers hope for better pain management options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…